| Assessment Status | Rapid Review Complete |
| HTA ID | 20019 |
| Drug | Naloxone |
| Brand | Nyxoid® |
| Indication | Intranasal spray is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid® is indicated in adults and adolescents aged 14 years and over. Nyxoid® is not a substitute for emergency medical care. |
| Assessment Process | |
| Rapid review commissioned | 14/04/2020 |
| Rapid review completed | 12/05/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that naloxone (Nyxoid®) intranasal spray be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement March 2021.
